Pyrimidin-6 yl acethydroxamic acids
United States Patent 1 Fauran et al.  
  [4 Apr. 8, 1975 PYRIMIDIN-6 YL ACETI&#39;IYDROXAMIC ACIDS [75] Inventors: Claude P. Faurari, Paris; Guy R.  
 Bourgery, Colombes; Jeannine A. Eberle, Chatou; Guy M. Raynaud, Paris; Claude J. Goure&#39;t, Meudon, all of France [73] Assignee: Delalande S.A., Courbevoie (Hauts de Seine), France 221 Filed: on. 24, 1972 211 Appl. No.: 299,672  
 [30] Foreign Application Priority Data OTHER PUBLICATIONS Smith. P. A. S., Open-Chain Nitrogen Compounds, Vol II, W. A. Benjamin, Inc. N.Y. 1966, pg. 95.  
 Primary Examiner-Lorraine A. Weinbergcr Assistant Examiner-Paul J. Killos Attorney, Agent, or FirmWoodhams, Blanchard and Flynn 57 ABSTRACT Compounds of the formula CH -CO-NHOH wherein R and R are alkyls having from 1 to 3 carbon atoms, or  
 is morpholino, pyrrolidino, piperidino and hexamethyleneimino, and  
 Ar is phenyl, phenyl mono= or polysubstituted with halogen, methoxy or me&#39;thylcarbonyloxy, 3,4- methylenedioxy phenyl, or 3-trifluoromethyl phenyl are prepared by reacting the corresponding 4-chloro- 6-ethyl acetate compound with a ts to obtain the 4-amino-6-ethyl acetate compound and then reacting the latter compound with hydroxylamine hydrochloride. The compounds possess analgesic and antiinflammatory properties.  
 8 Claims, No Drawings 1 PYRIMIDIN-6 YL ACETHYDROXAMIC ACIDS The present invention relates to pyrimidin-6 yl acethydroxamic acids. theirmethod of preparation and their therapeutic application.  
  The compounds according to the invention correspond to the formula 2 N 1 k on co-uaoa Ar N 2 in which:  
 R and R, each represent an alkyl radical containing from 1 to 3 carbon atoms, or together with the nitrogen atom to which they are attached form a heterocyclic radical selected from morpholino, pyrrolidino, piperidino and hexamethyleneimino; and  
 Ar. represents:  
 . phenyl radical which may be monoor polysubstituted by a halogen atom from fluoro. chloro and bromo. by a methoxy or a methylcarbonyloxy radical, 3.4-methylenedioxy phenyl radical. or 3-trifluoromethyl phenyl radical.  
 The method of preparation according to the inven-&#39; tion consists in reacting an acetic ester of formula:  
  N/ l (II) J CH2C00C2H5 2 ably substituted in the 2-position. of (4-chloropyrimidin-6 yl) ethyl acetate of formula:  
  N I 111 kN I CH2 COOCZH5 Ar in which:  
 -Ar has the same signification as in formula (I) with an amine of formula in which R and R also have the same signification as in formula (I) The preparation of [(Z-parachlorophenyl 4-pyrrolidino)-pyrimidin-6 yl] acethydroxamic acid, of code No. 7 l .224, is given by way of example to illustrate the present invention.  
 0.1 mole of hydroxylamine hydrochloride in solution in 125 c.c. of methanol is added to a solution of 0.2 mole of sodium methanolate in 200 c.c. of methanol.  
 The sodium chloride formed is filtered off. Over a period of 10 minutes, 0.1 mole of the ethyl ester of [(2-pchlorophenyl 4-pyrrolidino)-pyrimidin-6 yl] acetic acid is added to the filtrate, with agitation. The reaction.  
 mixture is left with agitation at ambient temperature until dissolution in the filtrate of said ethyl ester is just complete, and then the agitation is continued at the reflux temperature of methanol for one hour.  
  After cooling, the reaction mixture is slightly acidifled and then neutralised by the addition of sodium bicarbonate.  
  The product obtained is filtered and recrystallised from 96 alcohol.  
 Melting point I. l 8C Yield 51 Q Empirical formula C H CI N, O,  
 Elementary analysis: C H N Calculated 12 57.74 515 i684 Found &#39;2 57.64 495 10.91  
  The compounds listed in Tables I. la. l1; and l( are prepared by the method according to the preceding example. whilst Tables Id and le indicate the identification characteristics of synthesised intermediates of formula (ll). which intermediates are novel.  
 TABLEI x l l 7 Elementary analysis Code A: 1 Empirical l MOI- lm i NO 1 I Formula int Calculated l Fo u nd weight (0) I c(7;) EU) NW.) cot) 11(7.) N03 7101 I p.CIl.-C&#39; ll C H C1N O 346,81 209C 587. 58,37 5,52 16,16 53,71 5,27 15,37  
 71148 p.C1-C H C H n (2 11 01 N 0 362,85 140C 48% 59,58 6,39 15,44 59,64 6,37 15,64  
 C H n 71165 p.(;l-C H C H C1N 0 360,84 179C 52% 59,91 5,87 15,53 59,94 5,82 15,71  
 TABLE Ie- Continued The compounds of formula (I) have been tested on animals in the laboratory and have been shown to possess analgesic and antiinflammatory properties.  
 I. Analgesic properties The compounds of formula (I), administered orally to a mouse, are capable of reducing the number of painful stretchings caused by the intraperitoneal injection of acetic acid.  
  By way of examples, the results obtained with various compounds of formula (I) are given in Table ll.  
 TABLE ll C odc No Dose administered Percentage of reduction of (mg/kg/PO) the number of painful stretchings 7l l-l-X t) 65 &#39;71 7 I01 lOO 70 7t 71 I65 100 65 &#34;/2 71224 40 5O 92 2. Antiinflammatory properties These properties show themselves by a diminution of the local oedema. caused by the sub-planar injection of a phlogogenic agent, such as carragenin, in a rat followed by the oral administration of the compounds of formula (I).  
  By way of examples. the results obtained with various compounds of formula (I) are given in Table III.  
 general formula (l). together with a therapeuticallyacceptable carrier.  
 What we claim is:  
  is selected from the group consisting of morpholino. pyrrolidino, piperidino and hexamethyleneimino, and Ar is phenyl, or  
 phenyl monoor polysubstituted by fluoro, chloro or bromo, or by methylcarbonyloxy, or by methoxy,  
  or a 3,4-methylenedioxy phenyl or a 3-trifluoromethyl phenyl. 2. A compound as claimed in claim 1, in which Ar is p-chloro-phenyl, m-chlorophenyl or m-fluorophenyl.  
  3. A compounds as claimed in claim 1, in which Ar is 3,4,5-trimethoxy phenyl.  
  4. A compounds as claimed in claim 1, in which Ar is 3-trifluoromethyl phenyl.  
 TABLE III Code No Dose Administered Percentage diminution of (mg/kg/PO) the oedema The compounds of formula (I) tested, showed a weak toxicity, since no mortality in the mouse was produced by an administered dose of 2g/kg/PO. Accordingly, the difference between the lethal dose and the pharmacologically-active dose, mentioned in the preceding examples, is sufficiently great to permit the compounds of formula (I) to be utilised in therapeutics.  
  The compounds of formula (I) are suitable for use in the treatment of inflammatory and other pains. They 5. A compound as claimed in claim &#39;1, in which R 0 and R are indentical alkyls.  
  6. A compound as claimed in claim 1, in which R, and R2 each represent methyl, ethyl or n-propyl.  
 4 7. A compound as claimed in claim 1, in which is selected from the group consisting of pyrrolidino, pi-&#39; peridino and hexamethyleneimino.  
 8. A compound as claimed in claim 1, in which may be administered by oral means in the form of tablets, sugar-coated. pills or gelules containing 25 to 500 mg. of active ingredient l to 5 times a day) and by rectal means in the form of suppositories containing 25 to 250 mg of active ingredient (l to 2 times a day).  
  Accordingly, the present invention also relates to a therapeutic composition comprising a compound of the is morpholino.